CONFERENCE UPDATE: ILC 2022

Screening and cooperation model of HCV elimination in ouy-patients and PWIDs

GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Glossary: Ab: Antibody; GOP: General out-patient; HCC: Hematocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; PWID: People who inject drug; RNA: Ribonucleic acid; SOF/VEL: Sofosbuvir/velpatasvir

References
  1. Lin Q, et al. From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China. Presented at: The International Liver Congress. 2022; 22-26 June 2022; London, UK.
  2. Lin Q, et al. From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China. J Hepatol 2022; 77 (Supple 1); S559-S560.
HCV
PWID
People who inject drugs
SOF/VEL
Related Articles

New paradigms in hepatitis management to address treatment challenges and barriers to care

In a webinar organized by the Hong Kong Association for the Study of Liver Diseases (HKASLD), Professor Kim, Seung-Up and Dr. Wong, Yu-Jun Eugene introduced the new paradigms in viral hepatitis disease control. While Prof. Kim discussed some topics of hepatitis B virus (HBV) management, including the increased risk of kidney disease with long-term antiviral use and the appropriate first-line agents to mitigate this risk, Dr. Wong presented the challenges of hepatitis C virus (HCV) management and access to care, highlighting the efficacy and safety of the direct-acting antiviral (DAA) treatment of sofosbuvir/ velpatasvir (SOF/VEL) in HCV patients and the simplified treatment monitoring in reducing the healthcare burden.
GASTROENTEROLOGY & HEPATOLOGY
17 Jan 2023

Evaluation of the clinical and economic values of SOF/VEL in CHC patients
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Changing HCV patient profiles from large multinational real-world SOF/VEL dataset

Glossary: DAA: Direct-acting antiviral; GT3: Genotype 3; HCV: Hepatitis C virus; IV: Intravenous; LFU: Lost to follow-up; NS5A: Nonstructural protein 5A; RBV: Ribavirin; RNA: Ribonucleic acid; SOF/VEL: Sofobuvir/velpatasvir; SVR: Sustained virologic response

GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Health economic outcome of A5360 MINMON

Glossary: DAA: Direct-acting antiviral; HCV: Hepatitis C virus; RNA: Ribonucleic acid; SoC: Standard of care; SOL/VEL: Sofosbuvir/velpatasvir; SVR: Sustained virologic response; the US: The United States
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

HCC incidence after HCV cure among patients with advanced fibrosis of cirrhosis

Glossary: aRR: Adjusted rate ratio; CI: Confidence interval; HCC: Hematocellular carcinoma; HCV: Hepatitis C virus

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY
08 Nov 2022

Predictive factors for LFU pre- and post-HCV treatment

Glossary: BC: Breast cancer; HCV: Hepatitis C virus; IDU: Injection drug user; LFU: Lost to follow-up; OR: Odds ratio; RNA: Ribonucleic acid; SVR: Sustained virologic response

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY ...
08 Nov 2022